Medication info
Telostop Tablet 80/20 mg

Telostop Tablet 80/20 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Ildong Pharmaceutical Co., Ltd.
Appearance
white oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/Alu-Alu)x3], 30 tablets/bottle
Approval status
Active

MFDS item code 201504098 · Approved 2015.06.23 · Insurance code 642905490

Summary

Main use
Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and reduction of cardiovascular risk
Who takes it
Adults
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients achieve control at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Ildong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia, inhibition of the progression of atherosclerosis, and reduction of cardiovascular risk

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attacks
  • clinical evidence of damage to peripheral organs
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This medication is suitable for patients who need to use telmisartan and rosuvastatin simultaneously. Telmisartan lowers blood pressure in patients with essential hypertension and helps reduce the risk of myocardial infarction, stroke, and cardiovascular mortality in individuals over 55 years of age who are at high risk for cardiovascular diseases. Rosuvastatin lowers cholesterol levels in patients with primary and mixed hyperlipidemia in conjunction with diet and delays the progression of atherosclerosis, thereby reducing the risk of cardiovascular diseases. It is also used to reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk groups with elevated high-sensitivity C-reactive protein. Thus, both ingredients improve cardiovascular health through management of blood pressure and cholesterol.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily. A dose of 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. When this medicine is administered in combination with a thiazide diuretic such as hydrochlorothiazide, it produces an additional blood pressure-lowering effect. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after the start of treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients achieve control at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Precautions

This medication should not be used during pregnancy as it can cause serious harm to the fetus and newborn; if pregnancy is confirmed, discontinue use immediately. Individuals who are allergic to this medication or its components, pregnant women or those who may become pregnant, and breastfeeding women should not take this medication. Patients with severely impaired liver function or problems with bile excretion, those with severely reduced kidney function, or patients with certain genetic muscle disorders should avoid using this medication. Elderly patients or those with high potassium levels in the blood, and patients with slightly impaired liver function should use this medication with caution; regular blood tests and health checks are necessary. This medication can cause muscle pain or weakness, and in severe cases, rhabdomyolysis where muscle tissue is destroyed, so if you experience symptoms like muscle pain or weakness while taking this medication, consult a doctor immediately. Liver function abnormalities may also occur, so liver enzyme levels should be checked regularly and if abnormalities are found, discontinue use. This medication may interact with other drugs, so if you are taking other medications, be sure to inform your doctor or pharmacist. In case of overdose, symptoms such as hypotension, dizziness, and acute renal failure may appear, requiring immediate medical attention. Caution is advised when driving or operating machinery as this medication may cause dizziness or drowsiness.

Side effects

Headache, positional dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver failure, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin eruption, eczema, urticaria, myalgia, lumbago, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, asthenia, influenza-like illness, increased serum creatinine, increased serum uric acid, elevated serum CK, decreased hemoglobin, hypoglycemia, angioedema, hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, headache, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, anorexia, arrhythmia, asthenia, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, syncope, widespread pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. The safe storage temperature is at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

white oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/Alu-Alu)x3], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.